Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and DLI for Relapse Prevention Post-HSCT
NCT02458235Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Jun 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), sponsored by University of California, San Francisco. Started Jun 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)juvenile myelomonocytic leukemia (JMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02458235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458235.